(TCON) - Earnings & Price History

TCON: - 2.925, $47.47M, 0.08 (2.63%)

Sector: Healthcare - Industry: Biotechnology

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration, and fibrotic diseases. Its lead product candidate is TRC105, which is in Phase II clinical trials for oncology indications, including soft tissue sarcoma, renal cell carcinoma, glioblastoma, and hepatocellular carcinoma. The companys other product candidates comprise TRC205, an endoglin antibody that is in preclinical stage for the treatment of fibrotic diseases; and TRC102, a small molecule, which is in clinical development for the treatment of lung cancer and glioblastoma. TRACON Pharmaceuticals, Inc. has collaboration agreements with National Cancer Institute and Santen. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, I

Past TCON reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-02-28AMC-0.5343.93.93.94.052.56%2.56%64.23K
2017-02-17AMC-0.53
2017-02-16AMC-0.533.9543.953.853.95-1.25%-1.25%13.62K
2016-11-08AMC-0.635.75.65.855.4564.46%▲-2.56%1.79%46.95K
2016-11-01AMC-0.635.35.455.875.155.877.71%▲-9.71%-2.75%31.61K
2016-08-10AMC-0.625.765.565.35.36.05-4.68%8.68%3.60%17.68K
2016-08-03AMC-0.625.66225.365.55.35.66222.61%2.95%5.64%16.18K
2016-05-11AMC-0.766.296.216.186.136.49-0.48%1.78%1.29%16.01K
2016-02-18AMC-0.646.357.176.456.147.23-10.04%-1.55%-11.44%79.00K
2015-11-03AMC-0.5110.2810.878.758.7510.46-19.50%▲17.49%-5.43%89.97K

Login | Register
Monday Dec 10, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades